The company has a collaboration with Merck, and there are far worse partners you could have when working in the cancer segment of biotech.
Let's see what we might expect.
The drugmaker's shares are up about 50% since last July and could use a rest, but are likely to move higher longer term.
Investors may consider dosing up on the long side of this vaccine provider.
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
Let's check out two charts.
It looks like JNJ has its swagger back.
Two food-related names and one in health care look like promising investments right now.
Time to review the charts and indicators.
As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.